alemtuzumab (Campath) (cont.)

Pharmacy Author:
Medical and Pharmacy Editor:

DOSING:

  • Alemtuzumab is given by intravenous infusion over 2 hours. The dose should be gradually increased to the recommended dose of 30 mg/day three times per week for 12 weeks.
  • Medications that should be given during alemtuzumab therapy to prevent side effects and infections include oral antihistamines, acetaminophen (Tylenol), trimethoprim/sulfamethoxazole DS (Bactrim DS), and famciclovir (Famvir).

DRUG CLASS AND MECHANISM:

  • Alemtuzumab is an injectable drug used for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). People with CLL have too many of a type of white blood cell called lymphocytes in the blood and bone marrow. Alemtuzumab is an antibody that targets a protein called CD52 that is found on the surface of the lymphocytes. Alemtuzumab attaches to lymphocytes and then activates the immune system to help kill the lymphocytes.
  • The FDA approved alemtuzumab in May, 2001.

REFERENCE: FDA Prescribing Information


Medically Reviewed by a Doctor on 6/15/2016


Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Pill Finder Tool

Need help identifying pills and medications?
Use the pill identifier tool on RxList.


Back to Medications Index

Health Solutions From Our Sponsors